Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Review of hedge fund launches, closures, trends, regulatory and legal events - week 17

Sunday, May 02, 2010

Benedicte Gravrand, Opalesque London:

Last week, we heard of fund launches from GHF (2 credit funds); Highland Capital (All Cap Equity Value); LGT Capital (UCITS III accessing managed futures strategy); Private Advisors; EM Capital (ESG EM); Providence AM (credit opps); Lyxor AM and Martin Currie (China fund on Lyxor's Hedge Fund Managed Account Platform); and Checchi Capital (distressed). Cadogan Management liquidated its Japan FoHFs following poor performance.

The Parker FX Index was up 0.78% for March (0.80% YTD), the Greenwich Composite Investable Hedge Fund Index was up 1.52% (+1.59% YTD); and the Morningstar 1000 Hedge Fund Index returned 2.8% (est.), 1.6% YTD, and funds in the index saw inflows of $2.6bn in February.

Hedge fund industry returns showed their lowest beta level since 2004, said Credit Suisse/Tremont; the Charles Schwab Corp. will allow advisers to hold in custody additional alternative investments once again; Hedgebay reported that in the secondary market trading, the highest number of trades had been completed so far in 2010; BlackRock said investors had slowed down on 're-risking' activities and shifted to passive funds; the combined fortunes of the top three hedge fund managers in the UK grew by GBP1.15bn last year, according to The Sunday Times Rich List 2010; Guillaume Rambourg is to return to a fund management role at Gartmore, and the firm’ shares jumped after the news.

The following trends were noted: BNY Mellon/Greenwich Associates said in a white paper on convergence between traditional invest......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for